3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Carcinoma, Renal Cell
2
Peritoneal Neoplasms
1
Neoplasm Metastasis
1
Melanoma
1
Lung Neoplasms
1
Kidney Neoplasms
1
Glioma
1
Glioblastoma
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Astrocytoma
1
Adenocarcinoma, Bronchiolo-Alveolar
1
Interventions
Temozolomide
29
Bevacizumab
15
Radiotherapy
13
antineoplaston AS 2-1
8
antineoplaston A10
8
Everolimus
7
Radiation
6
Erlotinib Hydrochloride
6
Radiotherapy, Intensity-Modulated
5
Lomustine
4
veliparib
3
palbociclib
3
Vorinostat
3
Sunitinib
3
Radiotherapy, Conformal
3
Magnetic Resonance Spectroscopy
3
Carmustine
3
Carboplatin
3
temsirolimus
2
selinexor
2
poly ICLC
2
etoposide phosphate
2
cabozantinib
2
Sirolimus
2
Nivolumab
2
Irinotecan
2
Immunoglobulin G
2
Imatinib Mesylate
2
Etoposide
2
Donepezil
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Astrocytoma
×
lentiviral minigene vaccine of COVID-19 coronavirus
×
Clear all
NCT02529072
2020-03-26
AVERT
Duke University
Phase 1
Completed
6 enrolled
11 charts